Allos would like to request redaction addition of clarification in the FDA Briefing Document to the Oncologic Drugs Advisory Committee on NDA[removed]in the following sections:

First Page		Document Content
Health Bone Medicine Pharmaceutical industry Amgen Denosumab Osteoporosis		Allos would like to request redaction addition of clarification in the FDA Briefing Document to the Oncologic Drugs Advisory Committee on NDA[removed]in the following sections: Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 62,26 KB Share Document on Facebook